- pharma
Efbemalenograstim alfa
CAS 2200269-79-8
Concern score
Not assessed — no hazard data yet.
Efbemalenograstim alfa in plain language
Also known as Efbemalenograstim alfa vuxw · Efbemalenograstim Alfa-VUXW · Benegrastim · Recombinant dimeric g-csf fusion protein F627 · Rh g-csf fc fusion protein F-627 · F-627
Show all 8 names
F627 · Ryzneuta
We don't have a plain-language description for Efbemalenograstim alfa yet.
- We haven't assessed a concern score for this ingredient yet.
Regulation
No restrictions found. Efbemalenograstim alfa appears in these published regulatory listings.
- In marketed US drugs
USFDAmarketed drug occurrenceFDA NDC lists this ingredient in 1 active drug products and 1 total products.
- FDA NDC lists this ingredient in 1 active drug products and 1 total products.Source →
Evidence & sources
No graded research studies for Efbemalenograstim alfa yet. This record is compiled from the published data sources below — registries and regulatory listings, not study findings.
Where this comes from
Reference links (1)
Allergen profile
Canonical allergen markers detected on this ingredient. Each row is derived from the ingredient’s name or synonyms matching a known allergen class — useful when scanning a label for a specific allergy context.
- EggContains · Oral (ingested)
Source: chemindex_name_match
Suitability
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Fragrance avoidance
Nothing to weigh for this context yet.
We have no published hazard signal for this ingredient, so we cannot say how it behaves in this context — that is missing evidence, not a clean result.
Where it has been recorded
How often FDA National Drug Code directory has listed Efbemalenograstim alfa in a product composition. These are source records, not Greenveil catalog products.
Source records
1